News | Wearables | June 01, 2017

Northwell Health Partners With Peerbridge Health on Remote Patient Monitoring

Companies conducted clinical trial comparing Peerbridge Cor multi-channel ECG monitor

Northwell Health Partners With Peerbridge Health on Remote Patient Monitoring

June 1, 2017 — Northwell Health recently announced a new partnership agreement with Peerbridge Health Inc., to explore the future of remote medical monitoring. Peerbridge technology enables remote patient monitoring through multiple on-body wireless sensors.

To better understand the potential of this partnership, Peerbridge Health and Northwell conducted a clinical trial to measure the performance of the company’s flagship product, the Peerbridge Cor, a compact, lightweight, multi-channel electrocardiogram (ECG) monitor. To ensure efficacy, the Peerbridge Cor was compared to other cardiovascular monitors in a clinical trial.

“The trial demonstrated this technology was superior to the current Holter monitor standard,” said Nicholas Skipitaris, M.D., chief of electrophysiology at Lenox Hill Hospital in New York City. “Not only did the Peerbridge Cor deliver excellent, multi-channel, analyzable data, but it delivered less motion artifact and fewer false positives, despite our patient’s active New York lifestyle.”

The American Heart Association reports cardiovascular disease and stroke as the top two killers of American adults. Cardiovascular monitoring, both inside and outside medical environments, is critical for diagnosis, proper treatment and improved outcomes.

According to the U.S. Center for Disease Control & Prevention Foundation, annual direct medical costs associated with cardiovascular diseases are projected to rise to more than $818 billion by 2030. To get ahead of the growth in patient demand, an increasing number of providers are looking for more efficient monitoring to improve treatment and deliver better outcomes, which also has the potential to significantly reduce expenses.

For more information: www.peerbridgehealth.com

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init